StreetInsider.com News Articles

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Fri, 02 Oct 2026 09:00:00 -0400

- Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors -

- Findings provide additional mechanistic rationale for upcoming Phase 2 study of atebimetinib in combination with PD-1 blockade in lung cancer patients -

NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a poster will be presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 4-8, 2026, in Phoenix, AZ,

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Fri, 02 Oct 2026 09:00:00 -0400

- Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors -

- Findings provide additional mechanistic rationale for upcoming Phase 2 study of atebimetinib in combination with PD-1 blockade in lung cancer patients -

Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer

Mon, 28 Sep 2026 07:30:00 -0400

- Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark study -

- Patients with stable or increased weight at three months had significantly longer overall survival than patients who lost weight at three months -

- Overall survival was comparable among patients with moderate and deeper tumor volume reductions, suggesting presence of tumor reduction may be more important than depth of response -

- Findings support atebimetinib’s mechanisms designed to extend survival including tumor volume reduction and

Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer

Mon, 28 Sep 2026 07:30:00 -0400

- Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark study -

- Patients with stable or increased weight at three months had significantly longer overall survival than patients who lost weight at three months -

- Overall survival was comparable among patients with moderate and deeper tumor volume reductions, suggesting presence of tumor reduction may be more important than depth of response -

- Findings support atebimetinib’s mechanisms designed to extend survival including tumor volume reduction and

Immuneering to Present at the ESMO Congress 2026

Thu, 24 Sep 2026 07:30:00 -0400

- Trial in progress poster will highlight the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer patients -
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a trial in progress abstract featuring the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) for the treatment of first-line pancreatic cancer (NCT07562152) has been accepted for poster presentation at the European Society for Medical

Immuneering to Present at the ESMO Congress 2026

Thu, 24 Sep 2026 07:30:00 -0400

- Trial in progress poster will highlight the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer patients -
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a trial in progress abstract featuring the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) for the treatment of first-line pancreatic cancer (NCT07562152) has been accepted for poster presentation at the European Society for Medical

Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival

Thu, 10 Sep 2026 07:30:00 -0400

- Expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib + mGnP maintained or gained weight at three months -

- New analyses evaluate the overall survival implications of both preserving body mass and reducing tumor volume -

NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers

Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival

Thu, 10 Sep 2026 07:30:00 -0400

- Expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib + mGnP maintained or gained weight at three months -

- New analyses evaluate the overall survival implications of both preserving body mass and reducing tumor volume -

NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers

Immuneering to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 16:05:00 -0400

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management plans to participate in the following upcoming investor conferences:

Cantor Global Healthcare Conference (September 9-11 in New York City)

Format: Fireside Chat and 1x1 Investor Meetings
Date/Time: Thursday, September 10, 2026, from 2:45-3:15 pm ET

H.C. Wainwright 28th Annual Global Investment Conference (September 14-16 in New York City)

Format: Fireside Chat and 1x1 Investor Meetings

Immuneering to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 16:05:00 -0400

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management plans to participate in the following upcoming investor conferences:

Cantor Global Healthcare Conference (September 9-11 in New York City)

Format: Fireside Chat and 1x1 Investor Meetings
Date/Time: Thursday, September 10, 2026, from 2:45-3:15 pm ET

H.C. Wainwright 28th Annual Global Investment Conference (September 14-16 in New York City)

Format: Fireside Chat and 1x1 Investor Meetings

H.C. Wainwright Reiterates Buy Rating on Immuneering Corporation (IMRX)

Thu, 27 Aug 2026 07:08:13 -0400

H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $14.00 price target on Immuneering Corporation (NASDAQ: IMRX).
The analyst commented: "The first approval of a RAS-directed therapy in metastatic pancreatic cancer is an important milestone for the field, but we do not view it as weakening the atebimetinib thesis. If anything, we think the initial investor reaction risks are conflating two very different clinical opportunities. The newly approved therapy is positioned in second-line metastatic disease, while atebimetinib is already enrolling a global randomized Phase 3 study in previously untreated patients, where the unmet need remains considerably larger. More importantly, atebimetinib

Immuneering touts Phase 3 trial as FDA clears new pancreatic cancer drug

Wed, 26 Aug 2026 17:16:26 -0400

Immuneering Corporation (Nasdaq: IMRX) responded to the FDA's approval of a new second-line treatment for metastatic pancreatic cancer, reiterating its focus on first-line patients through its ongoing Phase 3 trial, MAPKeeper 301.

MAPKeeper 301 is a global, randomized trial evaluating atebimetinib in combination with chemotherapy in patients with first-line metastatic pancreatic cancer. The trial has more than 35 locations listed on ClinicalTrials.gov and is currently enrolling patients.

Immuneering previously reported results from a Phase 2a study of atebimetinib 320 mg once daily plus modified gemcitabine/nab-paclitaxel in 55 first-line metastatic pancreatic cancer patients. As of an April 24, 2026 data cutoff, with a

Immuneering touts Phase 3 trial as FDA clears new pancreatic cancer drug

Wed, 26 Aug 2026 17:16:26 -0400

Immuneering Corporation (Nasdaq: IMRX) responded to the FDA's approval of a new second-line treatment for metastatic pancreatic cancer, reiterating its focus on first-line patients through its ongoing Phase 3 trial, MAPKeeper 301.

MAPKeeper 301 is a global, randomized trial evaluating atebimetinib in combination with chemotherapy in patients with first-line metastatic pancreatic cancer. The trial has more than 35 locations listed on ClinicalTrials.gov and is currently enrolling patients.

Immuneering previously reported results from a Phase 2a study of atebimetinib 320 mg once daily plus modified gemcitabine/nab-paclitaxel in 55 first-line metastatic pancreatic cancer patients. As of an April 24, 2026 data cutoff, with a

Immuneering touts Phase 3 trial as FDA clears new pancreatic cancer drug

Wed, 26 Aug 2026 17:16:26 -0400

Immuneering Corporation (Nasdaq: IMRX) responded to the FDA's approval of a new second-line treatment for metastatic pancreatic cancer, reiterating its focus on first-line patients through its ongoing Phase 3 trial, MAPKeeper 301.

MAPKeeper 301 is a global, randomized trial evaluating atebimetinib in combination with chemotherapy in patients with first-line metastatic pancreatic cancer. The trial has more than 35 locations listed on ClinicalTrials.gov and is currently enrolling patients.

Immuneering previously reported results from a Phase 2a study of atebimetinib 320 mg once daily plus modified gemcitabine/nab-paclitaxel in 55 first-line metastatic pancreatic cancer patients. As of an April 24, 2026 data cutoff, with a

Immuneering touts Phase 3 trial as FDA clears new pancreatic cancer drug

Wed, 26 Aug 2026 17:16:26 -0400

Immuneering Corporation (Nasdaq: IMRX) responded to the FDA's approval of a new second-line treatment for metastatic pancreatic cancer, reiterating its focus on first-line patients through its ongoing Phase 3 trial, MAPKeeper 301.

MAPKeeper 301 is a global, randomized trial evaluating atebimetinib in combination with chemotherapy in patients with first-line metastatic pancreatic cancer. The trial has more than 35 locations listed on ClinicalTrials.gov and is currently enrolling patients.

Immuneering previously reported results from a Phase 2a study of atebimetinib 320 mg once daily plus modified gemcitabine/nab-paclitaxel in 55 first-line metastatic pancreatic cancer patients. As of an April 24, 2026 data cutoff, with a

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both